Sarcoma Drugs Market Poised For Growth With Targeted Drug Innovations

The global sarcoma drugs market was estimated at USD 1,287 million in 2022 and is projected to reach USD 2,534.5 million by 2030, representing a compound annual growth rate (CAGR) of 8.9% during the 2023-2030 period. The growth is driven by increasing use of novel treatments, a strong developmental pipeline, rising incidence of soft tissue sarcomas (STS), and expanding R&D efforts.

Key Market Trends & Insights and Market Size & Forecast

• One major trend is the dominance of the targeted therapy and “others” segment in treatment type, having accounted for the largest share in 2022.
• On the regional front, North America held the largest revenue share — 49.1% in 2022.
• Meanwhile, the Asia Pacific region is expected to grow the fastest, with a projected CAGR of 9.6% through the forecast period.
• In terms of distribution channels, hospital pharmacies were the leading channel in 2022 with approximately 45% share.
• The online pharmacy segment is slowly gaining traction and is anticipated to be the fastest-growing channel during the forecast period, estimated at a CAGR of around 10.4%.
• Looking in more detail at disease incidence and pipeline, the annual incidence of STS globally is roughly 2 – 3 per 100,000 people; STS accounts for about 87.0% of all sarcoma cases, while malignant bone sarcomas make up the remaining ~13%.
• For example, in the U.S. in 2022, around 17,000 diagnoses and approximately 7,230 deaths from sarcoma were reported.

The pipeline is robust: checkpoint inhibitors (PD-1/PD-L1) are under evaluation for STS in multiple Phase I/II trials, and out of around 45 drugs in the clinical pipeline, 12 are molecular targeted drugs for STS and bone sarcoma treatment. Cancer vaccines and gene therapies are also attracting interest.

Order a free sample PDF of the Sarcoma Drugs Market Intelligence Study, published by Grand View Research.

Key Companies & Market Share Insight

In the competitive landscape, companies are leveraging several strategic levers: R&D investment to identify novel therapeutic targets; adoption of personalized medicine approaches for specific sarcoma subtypes or biomarkers; strategic partnerships with academic institutions and other pharma firms; clinical trial expansion, label extensions, and post-approval research; strong relationships with clinicians and healthcare providers; innovative pricing and reimbursement strategies; and manufacturing/supply-chain optimization.

An example of recent activity: in May 2023, one firm announced that its drug candidate larotrectinib sulfate entered Phase II trials for both adult and pediatric solid tumour sarcoma cases.

In March 2022, a biotech company formed a collaboration combining its RNAi therapeutic platform with another firm’s T-cell tumour infiltration technology to develop cancer drugs.

Key Companies List

Major players in the global sarcoma drugs market include:

• Pfizer Inc.
• Novartis AG
• Eli Lilly and Company
• Bayer AG
• Eisai Co., Ltd
• Johnson & Johnson
• Merck & Co., Inc.
• Daiichi Sankyo Company, Limited

Conclusion

Overall, the sarcoma drugs market is on a steady upward trajectory, underpinned by growing incidence of soft tissue sarcomas, strong drug-development momentum, and enhanced access and awareness globally. With targeted therapies firmly leading treatment types, and online distribution channels and emerging regional markets (such as Asia Pacific) poised for accelerated growth, companies with strong R&D, strategic partnerships, and agile market access strategies are well-positioned to capitalise. The presence of a deep clinical pipeline and an increasingly favourable regulatory and reimbursement environment further reinforce the expectation of sustained growth through to 2030.

Explore Horizon Databook – The world’s most expansive market intelligence platform developed by Grand View Research.